TCGA-85-6798-01A-11R-1949-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 57
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.480
- MYC_TARGETS_V1+0.460
- MYC_TARGETS_V2+0.460
- HEDGEHOG_SIGNALING+0.450
- E2F_TARGETS+0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- MTORC1_SIGNALING+0.400
- G2M_CHECKPOINT+0.370
- HYPOXIA+0.340
- DNA_REPAIR+0.320
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.670
- INTERFERON_GAMMA_RESPONSE-0.560
- ALLOGRAFT_REJECTION-0.430
- IL6_JAK_STAT3_SIGNALING-0.410
- COMPLEMENT-0.340
- INFLAMMATORY_RESPONSE-0.340
- PROTEIN_SECRETION-0.290
- KRAS_SIGNALING_UP-0.150
- BILE_ACID_METABOLISM-0.140
- ANDROGEN_RESPONSE-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-A4CN-01A-11R-A24H-07 | — | cohortSQ2 | 0.925 |
| 2 | TCGA-22-5482-01A-01R-1635-07 | — | cohortSQ2 | 0.921 |
| 3 | C3L-02168 | — | cohortSQ2 | 0.887 |
| 4 | TCGA-43-A474-01A-11R-A24H-07 | — | cohortSQ2 | 0.883 |
| 5 | SRR35579803 | — | E | 0.857 |
| 6 | TCGA-43-6770-01A-11R-1820-07 | — | cohortSQ2 | 0.852 |
| 7 | TCGA-58-8391-01A-11R-2326-07 | — | cohortSQ2 | 0.850 |
| 8 | SRR12475151 | — | — | 0.847 |
| 9 | TCGA-92-7341-01A-31R-2045-07 | — | cohortSQ2 | 0.846 |
| 10 | R26 | — | — | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.460 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.320 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |